血清抗整合素αvβ6抗体在溃疡性结肠炎患者病情评估中的作用

The Role of Serum Anti-Integrin αvβ6 Antoantibody in the Disease Assessment of Patients with Ulcerative Colitis

摘要: 本研究旨在通过分析健康对照组和疾病不同分期时患者血清抗体αvβ6抗体水平的差异，探讨血清抗整合素αvβ6抗体在辅助诊断和评估溃疡性结肠炎患者病情中的作用。方法：本研究招募了139例在本院消化内科住院治疗并诊断为UC的患者和同期40例健康体检人群作为研究对象。收集研究对象的一般资料，比较抗整合素αvβ6抗体在UC组与对照组间、UC不同活动度各组间的差异，并分析该指标的临床价值。结果：(1) 活动期UC患者血清抗整合素αvβ6抗体水平显著高于健康对照。随着疾病活动程度加重，血清抗整合素抗体αvβ6抗体水平逐渐升高。(2) 抗整合素αvβ6抗体预测UC的AUC为0.964，敏感度为89.2%，特异度为99.1%。P值均<0.01。结论：活动期UC患者血清抗整合素αvβ6抗体水平较健康对照组显著升高，且与疾病活动度相关，可以为辅助诊断和评估UC的疾病活动度提供参考。

Abstract: Objective: This study aims to investigate the role of serum anti-integrin αvβ6 autoantibodies in the auxiliary diagnosis and evaluation of ulcerative colitis (UC) by analyzing differences in serum anti-integrin αvβ6 autoantibody levels between healthy controls and patients at various stages of UC. Methods: A total of 139 UC patients hospitalized in the Department of Gastroenterology, along with 40 healthy individuals who underwent physical examinations during the same period, were recruited as research subjects. General information was collected from all participants, and comparisons were made regarding anti-integrin αvβ6 autoantibody levels between the UC group and the control group, as well as among different disease activity subgroups within the UC cohort. The clinical utility of this biomarker was also assessed. Results: (1) Serum anti-integrin αvβ6 autoantibody levels were significantly higher in active UC patients compared to healthy controls. Furthermore, as disease activity increased, serum anti-integrin αvβ6 autoantibody levels progressively rose. (2) The area under the curve (AUC) for anti-integrin αvβ6 autoantibodies in predicting UC was 0.964, with a sensitivity of 89.2% and specificity of 99.1%. All P values were < 0.01. Conclusion: The serum anti-integrin αvβ6 autoantibody level in patients with active UC was significantly higher than that in the healthy control group, and was related to the disease activity, which can provide a reference for the auxiliary diagnosis and evaluation of the disease activity of UC.